University of California, Berkeley
Berkeley, California, 94720, United States
NCT Number: NCT01790919
Existing drug and talking therapies for major depressive disorder (MDD) fail to produce complete recovery. This study will determine if substantial improvements to one of the most promising therapies, cognitive therapy (CT), can be achieved by administering a carefully designed procedure to improve memory for the content of CT sessions. This is important because (a) memory deficits are common in MDD patients and (b) each CT therapy session typically covers a complex array of topics and various skills are taught.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Berkeley, California, 94720, United States
Background. Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders and a leading cause of disability worldwide. Existing therapies fail to produce complete recovery. Progress toward improving outcome must include innovations that are safe, powerful, inexpensive and simple (for fast and effective dissemination). The proposed research seeks to test one such innovation. We seek to improve outcome by improving memory for the content of cognitive therapy (CT) sessions. CT is one of the most promising approaches to the treatment of MDD, yet there is room for improvement.
We believe that adding memory enhancing strategies to CT may improve MDD outcome because: (a) MDD is often characterized by memory impairment, (b) there is evidence that the memory impairment is modifiable, (c) CT typically entails the activation of emotion, (d) emotion can impair or bias memory and (e) there is evidence that memory for the content of therapy sessions is poor.
Aim. To evaluate if a strategy designed to enhance memory for the content of CT sessions improves treatment outcome for MDD. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory. It is hypothesized that CT+Cognitive Support, relative to CT-as-usual, will be associated with improved depression outcome at the end of treatment and 6 months after the completion of treatment.
Research Plan. A small pilot feasibility RCT will be conducted on adults with MDD (n = 48) who will be randomized to one of two groups: (a) CT+Cognitive Support (n = 24) or (b) CT-as-usual (n = 24). Outcome measures will be taken at baseline, end of treatment, and 6 months after treatment. Long-term objective. To provide the pilot data needed to prepare a larger scale intervention study focused on improving outcomes by improving memory for the content of therapy sessions. The outcomes, if positive, will have major public health implications because simple, inexpensive memory enhancing strategies can be readily included as a standard feature in all psychosocial treatments for a broad range of mental illness. Project
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory.
Time frame: Change in IDS scores from pre-treatment to post-treatment (defined as within 2 weeks of completing the course of treatment, which is 14 sessions) to 6-month followup
Primary mood outcome
Time frame: Change in GAF scores from pre-treatment to post-treatment (defined as within 2 weeks of completing the course of treatment, which is 14 sessions) to 6-month followup
Primary impairment outcome
Time frame: Pre-treatment; Within 2 weeks of completing the course of treatment (14 sessions); 6 month followup
To determine the presence or absence of current DSM-IV-TR defined episodes of depression
Time frame: Pre-treatment; within 2 weeks of completing the course of treatment (14 sessions); 6-month followup
Time to relapse or recurrence
Time frame: Pre-treatment; within 2 weeks of completing the course of treatment (14 sessions); 6-month followup
Time frame: All patients receive 14 sessions of cognitive therapy for depression. The treatment sessions are video taped. A random subset of 20% of the tapes are selected for MSRS scoring. Average MSRS scores will be compared across the 2 groups.
This is a measure of the use of memory support by treatment providers.
Time frame: Completed at the end of Session 7, 14 and at 6 month FU. Patient Recall Task scores will be compared across the two treatment arms and over the three assessment points.
This is a measure of the content of treatment that patient's remember
Time frame: This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms
Estimate of IQ. Used to determine if IQ is a moderator of treatment.
Time frame: This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms
Measure of declarative memory. used to determine if baseline memory is a moderator of treatment outcome.
Time frame: CTRS coding will be conducted on randomly selected recordings of treatment sessions. Average CTRS scores will be compared across the two treatment arms
Measure of the quality of cognitive therapy
Time frame: The CEQ scores, measured at the end of the first therapy session, will be compared across the two treatment arms
A measure of treatment expectancies
Time frame: This measure is taken at baseline (pre-treatment) and will be compared across the two treatment arms
Assesses demographics including age, years of education and chronicity of depression that are used in moderator analysis
University of California, Berkeley
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07521358
Behavior, Behavioral Symptoms
Makassar, South Sulawesi, Indonesia
View Trial DetailsNCT01701258
Behavior, Behavioral Symptoms
Belmont, Massachusetts, United States
View Trial DetailsNCT06710912
Behavior, Behavioral Symptoms
Kota Bharu, Kelantan, Malaysia
View Trial DetailsNCT06708013
Behavior, Behavioral Symptoms
Ankara, Turkey (Türkiye)
View Trial Details